| Business

Become a contributor

Bookmark Econotimes

| Business

Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.

BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns

Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support

Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital

Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit

Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock

L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown

Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions

Lloyds Banking Group to Close Invoice Factoring Business by End of 2025

Nvidia and Groq Strike Strategic AI Inference Licensing Deal

Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio

Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy

Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue

Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch

Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring

Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation

Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey

©Econometrics LLC . All Rights Reserved.

Vical Provides Company Update at Biocom's Global Life Science Partnering Conference

Friday, February 24, 2017 8:00 PM UTC

SAN DIEGO, Feb. 24, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 2:15 p.m. PT on Thursday, March 2, at Biocom's Global Life Science Partnering Conference (La Jolla – March 1-2). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact:
Tony Ramos
(858) 646-1127
Website: www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel

FxWirePro- Major Crypto levels and bias summary

Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch

Solana's Alpenglow Upgrade: Dawn of Sub-Second Finality and Bullish Momentum

Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026

Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy

Altcoins Primed for January 2026 Surge: Whale Bets and Regulatory Tailwinds

Hashrate Highs and Miner Squeeze: Bitcoin Difficulty Closes 2025 at Record Level

Jazz Ensemble Cancels Kennedy Center New Year’s Eve Shows After Trump Renaming Sparks Backlash

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical Provides Company Update at Biocom's Global Life Science Partnering Conference

Editor's Picks

Welcome to EconoTimes